Janux Therapeutics, Inc.

Janux Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing tumor-activated immunotherapies for cancer and autoimmune diseases. The company's core mission is to transform the lives of patients by creating highly effective and well-tolerated therapies that selectively modulate T cells to fight disease without causing systemic safety issues.

The company leverages proprietary technology platforms, including Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulators (ARM). The TRACTr platform is designed to create T cell engagers that activate specifically within the tumor microenvironment, thereby minimizing off-target effects. Key product candidates include JANX007 and JANX014, both PSMA-TRACTr therapies targeting prostate cancer, and JANX013, a PSMA-TRACIr designed for combination with JANX007. The ARM platform is in early development for autoimmune diseases, with JANX011 as a lead candidate.

In recent news, Janux Therapeutics announced in April 2026 the discontinuation of clinical development for JANX008, an EGFR-targeted TRACTr, after its activity did not meet development criteria in a Phase 1a study. Concurrently, the company initiated a Phase 1 study for JANX014, a dual-masked PSMA-TRACTr for metastatic castration-resistant prostate cancer. Janux also received a $35 million milestone payment from Bristol Myers Squibb, stemming from a collaboration agreement. David Campbell, Ph.D., serves as the President and CEO, leading the company's efforts in precision-engineered immunotherapies.